CG Oncology, Inc. Common stock
CG Oncology, Inc. Common stock（CGON）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · CGON · 截至 2026年6月8日
活动摘要
买入笔数
1
P-Purchase only
卖出笔数
23
近12个月
买卖比
0.04
Buy/Sell (by trades)
整体情绪
CG Oncology, Inc. Common stock内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月8日
CGON 季度内部人买卖趋势
CGON 内幕交易卖出 · CGON 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 8, 2026
活跃内部人
近12个月交易最活跃 · CGON CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
CGON 高管卖出股份 · CGON 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Jun 4, 2026 | POST LEONARD E Director | Option | 1,000 | $600 | Form 4 |
| Jun 4, 2026 | POST LEONARD E Director | Sale | 1,000 | $55K | Form 4 |
| Apr 17, 2026 | Mulay James Director | Option | 15,600 | $571K | Form 4 |
| Apr 17, 2026 | Mulay James Director | Sale | 15,600 | $1.14M⚡ | Form 4 |
| Mar 16, 2026 | Mulay James Director | Option | 1,310 | $16K | Form 4 |
| Mar 16, 2026 | Mulay James Director | Option | 654 | $2K | Form 4 |
| Mar 16, 2026 | Mulay James Director | Sale | 1,310 | $83K | Form 4 |
| Mar 12, 2026 | Kuan Arthur CEO · Director | Option | 64,612 | $111K | Form 4 |
| Mar 12, 2026 | Kuan Arthur CEO · Director | Other | 1,847 | $111K | Form 4 |
| Mar 4, 2026 | Kuan Arthur CEO · Director | Option | 102,871 | $177K | Form 4 |
| Mar 4, 2026 | Kuan Arthur CEO · Director | Other | 2,871 | $177K | Form 4 |
| Jan 9, 2026 | Mulay James Director | Option | 10,491 | $132K | Form 4 |
| Jan 9, 2026 | Mulay James Director | Option | 654 | $2K | Form 4 |
| Jan 9, 2026 | Mulay James Director | Sale | 654 | $29K | Form 4 |
| Jan 9, 2026 | Mulay James Director | Sale | 10,491 | $556K | Form 4 |
| Nov 17, 2025 | POST LEONARD E Director | Option | 1,000 | $600 | Form 4 |
| Nov 17, 2025 | POST LEONARD E Director | Sale | 1,000 | $41K | Form 4 |
| Oct 13, 2025 | POST LEONARD E Director | Option | 1,000 | $600 | Form 4 |
| Oct 13, 2025 | POST LEONARD E Director | Sale | 1,000 | $43K | Form 4 |
| Oct 9, 2025 | Mulay James Director | Option | 5,903 | $22K | Form 4 |
| Oct 9, 2025 | Mulay James Director | Sale | 5,903 | $260K | Form 4 |
| Sep 30, 2025 | POST LEONARD E Director | Option | 5,000 | $3K | Form 4 |
| Sep 30, 2025 | POST LEONARD E Director | Sale | 5,000 | $200K | Form 4 |
| Sep 29, 2025 | Mulay James Director | Option | 12,755 | $23K | Form 4 |
| Sep 29, 2025 | Mulay James Director | Sale | 12,755 | $500K | Form 4 |
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 CGON 内幕交易
CGON 内幕交易
CG Oncology, Inc. Common stock（CGON）内幕交易数据来源于公司内部人（包括Mulay James (Director), POST LEONARD E (Director), Kuan Arthur (CEO · Director)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。CGON内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看CG Oncology, Inc. Common stock机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
CGON 内幕交易 · 5个问题CG Oncology, Inc. Common stock（CGON）的内部人包括高管和董事，如Mulay James (Director), POST LEONARD E (Director), Kuan Arthur (CEO · Director)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 8, 2026